CNS Pharmaceuticals (FRA:BE50) Debt-to-Equity: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BE50 CNS Pharmaceuticals Inc FRA:BE50
35 GF Score
Price €0.61
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals Debt-to-Equity?

CNS Pharmaceuticals FRA:BE50 35 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates FRA:BE50 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 962 Biotechnology companies, CNS Pharmaceuticals ranks better than 99.9% on this metric.

CNS Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. CNS Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. CNS Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €15.80 Mil. CNS Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CNS Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:BE50' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.07   Med: 0.02   Max: 300
Current: 0.01

During the past 9 years, the highest Debt-to-Equity Ratio of CNS Pharmaceuticals was 300.00. The lowest was -2.07. And the median was 0.02.

FRA:BE50's Debt-to-Equity is ranked better than
99.9% of 962 companies
in the Biotechnology industry
Industry Median: 0.16 vs FRA:BE50: 0.01

CNS Pharmaceuticals  (FRA:BE50) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CNS Pharmaceuticals Debt-to-Equity Related Terms

CNS Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Debt-to-Equity Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.06 0.05 -0.07 0.05 0.07

CNS Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.07 3.30 0.00

FRA:BE50 vs ALZN, SNGX, AIM: Debt-to-Equity Comparison

For the Biotechnology subindustry, CNS Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNS Pharmaceuticals Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's Debt-to-Equity falls into.


FRA:BE50
35GF Score
CNS Pharmaceuticals Inc FRA:BE50
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CNS Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.281 + 0) / 3.863
=0.07

CNS Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 15.798
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
CNS Pharmaceuticals (FRA:BE50) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CNS Pharmaceuticals and its competitors. According to the industry distribution chart, CNS Pharmaceuticals ranks #1 out of 962 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is CNS Pharmaceuticals' Debt-to-Equity too high?
CNS Pharmaceuticals' current Debt-to-Equity is 0.00. Based on the distribution chart, CNS Pharmaceuticals ranks #1 out of 962 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CNS Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' Debt-to-Equity compare to ALZN and SNGX?
According to the Biotechnology industry distribution chart, CNS Pharmaceuticals ranks #1 out of 962 companies for Debt-to-Equity. This places CNS Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CNS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CNS Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (FRA:BE50) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. CNS Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CNS Pharmaceuticals (FRA:BE50), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Other Exchanges CNSP:USA
Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
35GF Score

Get the complete analysis for FRA:BE50

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price